Institutional Biosafety Committee (IBC)Home » Compliance » Compliance Committees » Institutional Biosafety Committee (IBC)
Interim Laboratory Biosafety Guidance for Research with SARS-CoV-2 and IBC Requirements under the NIH Guidelines
Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)
Marti Benedict, RN, BSN
Location: 1109 Weiskotten Hall
Policy and Procedure Inquiries
Paul Massa, PhD, Chair of the Institutional Biosafety Committee
The Institutional Biosafety Committee (IBC) must review all research involving infectious agents, fresh human tissue or recombinant DNA.
SUNY Upstate Medical University expects that all research will be performed with the highest safety standards, to guarantee the safety of the public and Upstate's employees. The Institutional Biosafety Committee (IBC) is charged with ensuring that research is performed in a safe environment and in accordance with guidelines promulgated by the National Institutes of Health. The IBC will review all research conducted at or sponsored by Upstate Medical University or conducted by employees of Upstate Medical University which involves recombinant DNA, infectious, or bio-hazardous agents.
The IBC is authorized to inspect research facilities, approve research practices and procedures, and to take actions, such as enforcement or cessation of research activities, in the event of an unsafe workplace situation.
All human blood, fresh tissue, or body fluids must be regarded as possibly infected with blood borne pathogens such as Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV). Therefore, the Upstate IBC will review procedures for safe handling and may inspect Upstate research facilities where human blood, fresh human tissue, or body fluids are used, or research facilities used by Upstate research personnel, to ensure maximum safety.